943609-66-3
基本信息
維多組單抗
VEDOLIZUMAB ( 維多組單抗 )
Vedolizumab USP/EP/BP
常見問題列表
維多珠單抗(vedolizumab)是一種全人源化單克隆抗體,特異性拮抗α4β7整合素,抑制α4β7整合素對(duì)腸道黏膜細(xì)胞粘附分子MAdCAM-1的結(jié)合。
2014年5月,美國(guó)FDA批準(zhǔn)維多珠單抗上市,用于對(duì)常規(guī)療法或一種TNF-α拮抗劑不耐受、或不再響應(yīng)、或響應(yīng)不足的中度至重度活動(dòng)性潰瘍性結(jié)腸炎(UC)或克羅恩?。–rohn's disease,CD)成人患者的治療。
Integrin
Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC 50 =0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC 50 =0.02-0.06 g/mL) and fibronectin (IC 50 =0.02 g/mL), but not vascular cell adhesion molecule 1.
Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups.